Hardman & Co Equity Research & Stock Reports
- Professional research and all the latest forecasts, valuation opinions and multiples from Hardman & Co's expert analysts.
- Real-time updates from analysts following company announcements and other events.
- Near-live share prices, user-friendly dashboard, charting and company content.
Riding the carbon ceramic brake revolution
Surface Transforms manufactures and sells carbon ceramic brake discs. These discs offer major weight-saving and safety advances. We are in the early stages of dramatic demand growth. The company is the only alternative to the current nearmonopoly supplier, which is substantially owned by the family behind BMW. It is progressing with development for six auto OEMs’ potential new models, in volume contracts. Its new factory provides easily scalable supply. With proven expertise, test successes and years of low-level ‘pre-production’ sales, the business is at a major inflection point.
13 Jul 17
Promising start in the US
In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, highly competitive, portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments are benefiting from the trend away from intensive plastic surgery and represent a major growth opportunity. Products are sold directly in Europe and Brazil, and via distributors elsewhere globally. In a detailed trading statement, sales progress of products has been compared to the strong in-market demand, which augurs well for the full year. Silhouette InstaLift is continuing to gain sales traction in the US.
12 Jul 17
Major deal to supply Novartis CAR-T programmes
OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform. OXB has made two significant announcements during the past week which reduce risk and greatly improve sentiment towards the stock. First, refinancing of its existing loan with a new, more favourable debt facility from Oakland Capital. Secondly, a deal with Novartis to supply vector for use in the manufacture of certain CAR-T therapies.
07 Jul 17
ABZA AGY APH ARBB AVCT BUR CMH CLIG COS DNL EVG MCL MUR NSF ODX OXB PPH NIPT PHP PURP RE/ SCLP SPH VAL
The Monthly July 2017
As we approach 3rd January 2018 and the coming into force of the MiFID II legislation which changes the landscape for research, we are beginning to see some of the practical implications and complications. Brokers are in the early stages of working out how to structure charging for research, asset managers have already begun cutting their brokers’ lists and a model code of conduct for Research Payment Accounts for institutions has been published.
03 Jul 17
Making clinical progress
Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen’s proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. The results presentation is a good opportunity for Evgen to present the progress of its clinical pipeline. SFX-01 is progressing in two Phase II clinical trials for both subarachnoid haemorrhage (SAH) and ER+ metastatic breast cancer.
21 Jun 17
Hardman & Co Research and Daily Commentaries
Research Tree offers Hardman & Co research, providing ongoing coverage of 71 shares , as well as macro-economic categories including: Economic Data and Housing Market. We offer 199 reports from Hardman & Co on Research Tree.
Research reports provided by Hardman & Co
Companies covered by Hardman & Co
Sectors covered by Hardman & Co